JP2005535562A5 - - Google Patents

Download PDF

Info

Publication number
JP2005535562A5
JP2005535562A5 JP2003562155A JP2003562155A JP2005535562A5 JP 2005535562 A5 JP2005535562 A5 JP 2005535562A5 JP 2003562155 A JP2003562155 A JP 2003562155A JP 2003562155 A JP2003562155 A JP 2003562155A JP 2005535562 A5 JP2005535562 A5 JP 2005535562A5
Authority
JP
Japan
Prior art keywords
antibody
seq
c5ar
binding
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003562155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535562A (ja
JP4559081B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2003/000084 external-priority patent/WO2003062278A1/en
Publication of JP2005535562A publication Critical patent/JP2005535562A/ja
Publication of JP2005535562A5 publication Critical patent/JP2005535562A5/ja
Application granted granted Critical
Publication of JP4559081B2 publication Critical patent/JP4559081B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003562155A 2002-01-25 2003-01-24 抗Ｃ５ａＲ抗体及びその使用 Expired - Lifetime JP4559081B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35096102P 2002-01-25 2002-01-25
PCT/AU2003/000084 WO2003062278A1 (en) 2002-01-25 2003-01-24 MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009271989A Division JP5202501B2 (ja) 2002-01-25 2009-11-30 抗Ｃ５ａＲ抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2005535562A JP2005535562A (ja) 2005-11-24
JP2005535562A5 true JP2005535562A5 (enExample) 2006-02-23
JP4559081B2 JP4559081B2 (ja) 2010-10-06

Family

ID=27613447

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003562155A Expired - Lifetime JP4559081B2 (ja) 2002-01-25 2003-01-24 抗Ｃ５ａＲ抗体及びその使用
JP2009271989A Expired - Lifetime JP5202501B2 (ja) 2002-01-25 2009-11-30 抗Ｃ５ａＲ抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009271989A Expired - Lifetime JP5202501B2 (ja) 2002-01-25 2009-11-30 抗Ｃ５ａＲ抗体及びその使用

Country Status (11)

Country Link
US (3) US8071096B2 (enExample)
EP (2) EP1476469B1 (enExample)
JP (2) JP4559081B2 (enExample)
CN (2) CN102659945B (enExample)
AU (3) AU2003202297C1 (enExample)
CA (1) CA2476773C (enExample)
DK (1) DK2371861T3 (enExample)
ES (2) ES2561828T3 (enExample)
NZ (1) NZ534399A (enExample)
WO (1) WO2003062278A1 (enExample)
ZA (1) ZA200406347B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071096B2 (en) * 2002-01-25 2011-12-06 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
US7455837B2 (en) * 2002-11-05 2008-11-25 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
ZA200900954B (en) * 2006-08-22 2010-05-26 G2 Inflammation Pty Ltd Ant-C5aR antibodies with improved properties
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
US20100092493A1 (en) * 2007-03-06 2010-04-15 Novo Nordisk A/S Modulation of Complement System Activation for Treatment of Bleeding-Related Inflammation
CA2718588A1 (en) * 2008-02-19 2009-08-27 The Trustees Of The University Of Pennsylvania Complement inhibitors as therapeutic agents for treatment of cancer
CA2714296A1 (en) * 2008-02-20 2009-08-27 G2 Inflammation Pty Ltd Humanized anti-c5ar antibodies
NZ597259A (en) 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
WO2011100477A2 (en) * 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
EP2468295A1 (en) 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
ES2929575T3 (es) * 2011-06-06 2022-11-30 Novo Nordisk As Anticuerpos terapéuticos
ES2870004T3 (es) * 2012-08-21 2021-10-26 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
DK2994488T3 (da) * 2013-05-08 2022-10-03 Novo Nordisk As Anvendelse af c5ar-antagonister
WO2015080657A1 (en) * 2013-11-28 2015-06-04 Ge Healthcare Bio-Sciences Ab Stabilization of fermented beverages
EA201691481A1 (ru) * 2014-03-20 2017-02-28 Инфларкс Гмбх ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
US20220135658A1 (en) * 2019-03-14 2022-05-05 Morphosys Ag Antibodies targeting c5ar
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
WO2022033981A1 (en) 2020-08-12 2022-02-17 Innate Pharma Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab
US11912781B2 (en) 2021-01-13 2024-02-27 Visterra, Inc. Humanized complement 5A receptor 1 antibodies and methods of use thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
JPH02262599A (ja) 1989-01-03 1990-10-25 Merck & Co Inc ヒト多形核白血球からの精製Ｃ５ａレセプター
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5284746A (en) 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
CA2145278C (en) 1992-09-25 2009-03-10 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5480974A (en) * 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5861272A (en) * 1995-06-02 1999-01-19 Human Genome Sciences, Inc. C5A receptor
JPH08109200A (ja) 1994-08-19 1996-04-30 Takeda Chem Ind Ltd 抗Ｃ５ａレセプター抗体、その製造法および用途
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP0832231A2 (en) 1995-06-05 1998-04-01 Incyte Pharmaceuticals, Inc. A C5a-LIKE SEVEN TRANSMEMBRANE RECEPTOR
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
AU6035398A (en) 1997-01-31 1998-08-25 Incyte Pharmaceuticals, Inc. Human c5a-like receptor
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
WO2002038767A2 (en) 2000-11-07 2002-05-16 Genetics Institute, Llc. G protein-coupled receptor protein and nucleic acid molecules and uses therefor
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
DK1409646T3 (da) 2000-12-19 2012-08-06 Altor Bioscience Corp Transgene dyr omfattende et humaniseret immunsystem
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
DE60234944D1 (de) 2001-09-27 2010-02-11 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodiered assayverfahren
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US8071096B2 (en) 2002-01-25 2011-12-06 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
EP1581648A2 (en) 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
JP4754219B2 (ja) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
AU2004304665B2 (en) 2003-12-24 2009-03-12 Novo Nordisk A/S Transgenic non-human mammal comprising a polynucleotide encoding human or humanized C5aR
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
ZA200900954B (en) 2006-08-22 2010-05-26 G2 Inflammation Pty Ltd Ant-C5aR antibodies with improved properties
WO2008022391A1 (en) 2006-08-22 2008-02-28 G2 Inflammation Pty Ltd Method for producing antibodies
WO2008030564A2 (en) 2006-09-08 2008-03-13 Verenium Corporation Aglycosylated antibodies and methods of making and using those antibodies
WO2009053368A1 (en) 2007-10-22 2009-04-30 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
CA2714296A1 (en) 2008-02-20 2009-08-27 G2 Inflammation Pty Ltd Humanized anti-c5ar antibodies
WO2010000864A1 (en) 2008-07-04 2010-01-07 Novo Nordisk A/S Method for producing monoclonal antibodies
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант

Similar Documents

Publication Publication Date Title
US20250145718A1 (en) Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
KR102662387B1 (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
KR101853278B1 (ko) 치료학적 ｄｌｌ４ 결합 단백질
EP3683234A1 (en) Il-6r antibody and antigen binding fragment thereof and medical use
JP2009517057A5 (enExample)
JP2010501164A5 (enExample)
JP2022527151A5 (enExample)
JP2011526249A5 (enExample)
RU2009110154A (ru) АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ
JP2019505166A5 (enExample)
US8435522B2 (en) Humanized antibodies against CXCR3
JP2019507580A5 (enExample)
JP2023537958A (ja) Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
EP1708961A2 (en) Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
CN115368457A (zh) 抗tigit抗体及其用途
JP7643727B2 (ja) 抗－ｆｇｆ１９抗体
TW202602922A (zh) 結合構築體(二)
HK40049006B (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof
HK40049006A (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof
KR20250143755A (ko) 종양 괴사 인자 수용체 효능작용 mb
CA3255180A1 (en) Pharmaceutical composition for treating or preventing cancer with low HER2 expression
CN121517563A (zh) 人源化的靶向TfR1的抗体及其应用
HK40036076A (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof